PORT-2 + pembrolizumab

PORT-2 + pembrolizumab is an investigational combination therapy being evaluated for the treatment of advanced melanoma and non-small cell lung cancer (NSCLC), including both front-line and refractory settings. PORT-2 is a liposomal formulation of IMM60, a synthetic invariant natural killer T cell (iNKT) agonist designed to activate both the innate and adaptive immune systems by engaging iNKT cells, NK cells, and dendritic cells. This activation leads to secretion of pro-inflammatory cytokines and primes an adaptive immune response against tumors. Preclinical data show that PORT-2 increases PD-L1 expression on tumor cells and can restore sensitivity to anti-PD-1 therapy in resistant models. Pembrolizumab (Keytruda) is a humanized monoclonal antibody targeting programmed death receptor 1 (PD-1), blocking its interaction with PD-L1/PD-L2 to enhance T-cell mediated antitumor activity. The combination aims for synergistic immunomodulation—PORT-2 enhances tumor immunogenicity while pembrolizumab blocks inhibitory signaling—potentially expanding benefit to patients who do not respond to checkpoint inhibitors alone[1][2][3][5][6].

Brand names

Keytruda

Other names

IMM60 + pembrolizumabPORT-2 + KeytrudaPORT-2 + pembrolizumabLiposomal IMM60 + pembrolizumab